Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study-Reference-Cited by-同舟云学术

Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study

Published:2023-07-17 Issue:8 Volume:39 Page:1103-1118
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Ketkar Amita¹,Willey Vincent¹,Pollack Michael²,Glasser Lisa²,Dobie Casey³,Wenziger Cachet¹,Teng Chia-Chen²,Dube Christine²,Cunningham Dennis⁴,Verduzco-Gutierrez Monica⁵

Affiliation:

1. Carelon Research, Wilmington, DE, USA

2. AstraZeneca Biopharmaceuticals Medical, Wilmington, DE, USA

3. Xcenda LLC, Carrollton, TX, USA

4. Henry Ford Health, Detroit, MI, USA

5. UT Health San Antonio, San Antonio, TX, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2233819

Reference63 articles.

1. World Health Organization Emergency Response Team. COVID-19 Weekly Epidemiological Update: World Health Organization; 2023 [updated 22 February 2023; cited 2023 1 March]; 131:[Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19–-22-february-2023.

2. Centers for Disease Control and Prevention. COVID Data Tracker. Daily Update for the United States Atlanta, Georgia: Centers for Disease Control and Prevention; 2023 updated 2 March 2023; cited 2023 3 March]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.

3. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

4. Predicting severe outcomes in Covid-19 related illness using only patient demographics, comorbidities and symptoms

5. Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2: a Community-Based Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study;Advances in Therapy;2024-01-13

2. Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study;Biomolecules;2023-08-22